Article
A road map for the treatment of pediatric diffuse midline glioma.
Cancer cell - 8 Jan 2024
Koschmann Carl, Al-Holou Wajd N, Alonso Marta M, Anastas Jamie, Bandopadhayay Pratiti, Barron Tara, Becher Oren, Cartaxo Rodrigo, Castro Maria G, Chung Chan, Clausen Madison, Dang Derek, Doherty Robert, Duchatel Ryan, Dun Matthew, Filbin Mariella, Franson Andrea, Galban Stefanie, Garcia Moure Marc, Garton Hugh, Gowda Pruthvi, Marques Joana Graca, Hawkins Cynthia, Heath Allison, Hulleman Esther, Ji Sunjong, Jones Chris, Kilburn Lindsay, Kline Cassie, Koldobskiy Michael A, Lim Daniel, Lowenstein Pedro R, Lu Q Richard, Lum Joanna, Mack Stephen, Magge Suresh, Marini Bernard, Martin Donna, Marupudi Neena, Messinger Dana, Mody Rajen, Morgan Meredith, Mota Mateus, Muraszko Karin, Mueller Sabine, Natarajan Siva Kumar, Nazarian Javad, Niculcea Michael, Nuechterlein Nicholas, Okada Hideho, Opipari Valerie, Pai Manjunath P, Pal Sharmistha, Peterson Erik, Phoenix Timothy, Prensner John R, Pun Matthew, Raju G Praveen, Reitman Zachary J, Resnick Adam, Rogawski David, Saratsis Amanda, Sbergio Stefanie G, Souweidane Mark, Stafford James M, Tzaridis Theophilos, Venkataraman Sujatha, Vittorio Orazio, Wadden Jack, Wahl Daniel, Wechsler-Reya Robert J, Yadav Viveka Nand, Zhang Xu, Zhang Qiang, Venneti Sriram
Abstract excerpt
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3)...
Read the complete abstract on PubMed